Immuron CEO, Steven Lydeamore presentation to Coffee Microcaps Conference Melbourne, Australia

Immuron CEO, Steven Lydeamore presentation

to Coffee Microcaps Conference

Melbourne, Australia, September 16,

2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at

the Coffee Microcaps VIP Conference on Tuesday 16th September 2025 (9.45am Australian Eastern time) in Sydney.

A copy of the presentation being made

This release has been authorised by the

directors of Immuron Limited.

Chief Executive Officer

Immuron Limited (ASX: IMC, NASDAQ: IMRN),

is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for

the treatment of infectious diseases.

Travelan is an orally administered

passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea, a digestive tract disorder

that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan is a highly purified tabletized

preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent

colonization and the pathology associated with travelers' diarrhea. In Australia, Travelan is a listed medicine

on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers' Diarrhea, reduce

the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan is a licensed natural health

product (NPN 80046016) and is indicated to reduce the risk of Travelers' Diarrhea. In the U.S., Travelan is sold as a dietary

supplement for digestive tract protection.

Travelers' diarrhea (TD)

TD is generally defined as the passage

of 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting, abdominal cramps, fever, blood/mucus

in the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any resource-limited destinations (Leung

et al., 2006). Diarrhea continues to be the most frequent health problem among travelers to destinations in lower- and middle-income

regions (Steffen, 2017). Deployed US military personnel, essentially representing a long-term traveller population, are particularly

affected given their population dynamics and the context in which they seek care and treatment (Connor et al., 2012). Diarrhea

is the leading infectious disease threat to the overall health and preparedness of deployed US armed forces, with diarrheagenic E. coli,

Campylobacter spp., and Shigella spp. among the most commonly reported etiologies (Riddle et al., 2006).

Immuron Platform Technology

Immuron's proprietary technology is

based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of

producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the

acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract.

Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to the

bacteria found there. The underlying nature of Immuron's platform technology enables the development of medicines across a

large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the

Gastrointestinal tract and neutralize the toxins they produce.

IMM-124E (Travelan )

IMM-124E was developed using Immuron's

platform technology. IMM-124E is produced from the colostrum of birthing cattle that have been immunised during pregnancy with a vaccine

containing the outer antigens of multiple human derived ETEC. A total of 13 ETEC strains are used in the vaccine to produce high levels

of antibodies against selected surface antigens from the most common strains of ETEC. (Otto et al., 2011)

The resultant hyperimmune colostrum IMM-124E

from ETEC vaccinated cows contains significant levels of polyclonal antibodies specific for ETEC antigens LPS, CFA-I and Flagellin (Sears

The antibodies produced in IMM-124E have

been found to have a stronger binding and neutralizing activity (than the antibodies of unvaccinated cattle) against a wide range of LPS

antigens including both the variable O-polysaccharide region and the preserved oligosaccharide core R' region of LPS from

the 13 serotypes used in the ETEC vaccine.

IMM-124E is manufactured into a tablet form referred

Immuron is developing IMM-529 as an adjunctive therapy in combination

with standard of care antibiotics for the prevention and/or treatment of recurrent Clostridioides difficile infection (CDI). IMM-529 antibodies

targeting Clostridioides difficile (C. diff) may help to clear CDI infection and promote a quicker re-establishment of normal gut flora,

providing an attractive oral preventative for recurrent CDI.

Immuron is collaborating with Dr. Dena Lyras and her team at

Monash University, Australia to develop vaccines to produce bovine colostrum-derived antibodies. Dairy cows were immunised to generate

hyperimmune bovine colostrum (HBC) that contains antibodies targeting three essential C. diff virulence components. IMM-529 targets Toxin

B (TcB), the spores and the surface layer proteins of the vegetative cells.

This unique 3-target approach has yielded promising results

in pre-clinical infection and relapse models, including (1) Prevention of primary disease (80% P =0.0052); (2) Protection of disease recurrence

(67%, P <0.01) and (3) Treatment of primary disease (78.6%, P<0.0001; TcB HBC). Importantly IMM-529 antibodies cross-react with

whole cell lysates of many different human strains of C. diff including hypervirulent strains.

To our knowledge, IMM-529 is, to date, the only investigational

drug that has shown therapeutic potential in all three phases of the disease (Hutton et al., 2017).

Immuron has an exclusive distribution agreement

with Calmino goup AB for the territories of Australia and New Zealand for ProIBS . ProIBS - to help patients

treat IBS symptoms ProIBS is a certified medical device for the treatment of IBS symptoms such as abdominal pain, bloating

and unsettled bowel movements (diarrhoea and/or constipation). ProIBS contains AVH200 , derived from the

plant Aloe barbadensis. Mill. AVH200 has gel forming components which support the intestinal mucosal barrier. As IBS

is known to affect individuals for a long period of time, it is essential to have a treatment appropriate for long- term use -as

ProIBS is. The product is safe, and no interactions with other medications are known. Science-driven innovative Calmino

group AB, the developer of ProIBS , conducted a usability study among 1,003 users. PROIBS was helpful

for 94% of them. 91% of the users experienced an improvement in daily life and 98% would recommend PROIBS to someone

else. To learn more please check: www.proibs.eu.

Irritable bowel syndrome (IBS) is a common condition where

you experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits and stress levels

or mood. IBS affects around 3 out of every 10 people.

Females are more likely than males to be affected. Some key

symptoms of IBS include: abdominal pain or discomfort; stomach bloating and wind; chronic diarrhoea or constipation, or alternating between

the two.(healthdirect.gov.au) According to available data, the IBS treatment market in Australia is estimated to be a part of the

broader "Digestives & Intestinal Remedies" market, generating a revenue of around AU$221.14 million in 2025, with a projected

annual growth rate of 3.28%.(Statista)

Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea

during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012.

Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine

antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative. Sci Rep 7, 3665 (2017).

Leung AK, Robson WL, Davies HD. Travelers' diarrhea.

Adv Ther. Jul-Aug; 23(4): 519-27; 2006

Otto W, Najnigier B, Stelmasiak T and

Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic

Escherichia coli in volunteers Scandinavian Journal of Gastroenterology 46: 862- 868; 2011.

Riddle MS, Sanders JW, Putnam SD, and

Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers' (US military and similar populations): A systematic

review. American Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.

Sears KT, Tennant SM, Reymann MK, Simon

R, Konstantopolos N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia

coli Hyperimmune Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 1-14; 2017.

Steffen R. Epidemiology of travelers'